Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation

Beitrag in einer Fachzeitschrift

Details zur Publikation

Autorinnen und Autoren: Korompoki E, Filippidis FT, Nielsen PB, Del Giudice A, Lip GYH, Kuramatsu JB, Huttner H, Fang J, Schulman S, Marti-Fabregas J, Gathier CS, Viswanathan A, Biffi A, Poli D, Weimar C, Malzahn U, Heuschmann P, Veltkamp R
Zeitschrift: Neurology
Jahr der Veröffentlichung: 2017
Band: 89
Heftnummer: 7
Seitenbereich: 687-696
ISSN: 0028-3878
eISSN: 1526-632X


To perform a systematic review and meta-analysis of studies reporting recurrent intracranial hemorrhage (ICH) and ischemic stroke (IS) in ICH survivors with atrial fibrillation (AF) during long-term follow-up.A comprehensive literature search including MEDLINE, EMBASE, Cochrane library, clinical trials registry was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. We considered studies capturing outcome events (ICH recurrence and IS) for >=3 months and treatment exposure to vitamin K antagonists (VKAs), antiplatelet agents (APAs), or no antithrombotic medication (no-ATM). Corresponding authors provided aggregate data for IS and ICH recurrence rate between 6 weeks after the event and 1 year of follow-up for each treatment exposure. Meta-analyses of pooled rate ratios (RRs) were conducted with the inverse variance method.Seventeen articles met inclusion criteria. Seven observational studies enrolling 2,452 patients were included in the meta-analysis. Pooled RR estimates for IS were lower for VKAs compared to APAs (RR = 0.45, 95% confidence interval [CI] 0.27-0.74, p = 0.002) and no-ATM (RR = 0.47, 95% CI 0.29-0.77, p = 0.002). Pooled RR estimates for ICH recurrence were not significantly increased across treatment groups (VKA vs APA: RR = 1.34, 95% CI 0.79-2.30, p = 0.28; VKA vs no-ATM: RR = 0.93, 95% CI 0.45-1.90, p = 0.84).In observational studies, anticoagulation with VKA is associated with a lower rate of IS than APA or no-ATM without increasing ICH recurrence significantly. A randomized controlled trial is needed to determine the net clinical benefit of anticoagulation in ICH survivors with AF.

FAU-Autorinnen und Autoren / FAU-Herausgeberinnen und Herausgeber

Huttner, Hagen Prof. Dr.
Medizinische Fakultät

Einrichtungen weiterer Autorinnen und Autoren

Aalborg University
Careggi University Hospital / Azienda Ospedaliero Universitaria Careggi
Harvard University
Hospital de la Santa Creu i Sant Pau
Imperial College London / The Imperial College of Science, Technology and Medicine
Institute for Clinical Evaluative Sciences (ICES)
McMaster University
Universitätsklinikum Essen
Universitätsklinikum Würzburg
University Medical Centre Utrecht (UMC Utrecht)


Korompoki, E., Filippidis, F.T., Nielsen, P.B., Del Giudice, A., Lip, G.Y.H., Kuramatsu, J.B.,... Veltkamp, R. (2017). Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. Neurology, 89(7), 687-696. https://dx.doi.org/10.1212/WNL.0000000000004235

Korompoki, Eleni, et al. "Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation." Neurology 89.7 (2017): 687-696.


Zuletzt aktualisiert 2018-08-10 um 08:24